Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby
British Columbia
V5G 4W8
United States
Tel: 604-484-3300
Website: http://www.xenon-pharma.com/
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, USA – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders.
At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon’s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations.
Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
Stock Symbol: XENE
Stock Exchange: NASDAQ
151 articles with Xenon Pharmaceuticals Inc.
-
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
11/30/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022.
-
Xenon Pharmaceuticals to Participate in Upcoming November 2022 Investor Conferences
11/9/2022
Xenon Pharmaceuticals Inc. announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences.
-
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
11/7/2022
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately.
-
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
11/3/2022
Xenon Pharmaceuticals Inc. today announced the launch of its XEN1101 Phase 3 program with the initiation of the X-TOLE2 clinical trial, which will examine XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
11/1/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.
-
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
9/1/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.
-
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
8/8/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
8/2/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2022.
-
Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
7/11/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William Blair Biotech Focus Conference 2022 to be held July 12-13, 2022 in New York, NY.
-
Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
6/27/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares.
-
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
6/23/2022
Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 327,868 common shares pursuant to its existing shelf registration statement.
-
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
6/22/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced new, compelling efficacy data supporting the late-stage, Phase 3 development of XEN1101.
-
Xenon Pharmaceuticals Announces Proposed Public Offering - June 22, 2022
6/22/2022
Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.
-
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
6/21/2022
XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial.
-
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.
-
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
5/3/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “X-NOVA” clinical trial – to evaluate the safety, tolerability, and efficacy of XEN1101 in Major Depressive Disorder (MDD).
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update
5/3/2022
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022.